We report here that PP2A inhibition is a frequent event in breast cancer and identified PP2A hyperphosphorylation together with SET and CIP2A overexpression as molecular mechanisms that cooperate to inactivate this phosphatase. Here, PTPA is linked to breast carcinoma.